Literature DB >> 17472306

The pathogenesis of osteonecrosis.

Lynne C Jones1, David S Hungerford.   

Abstract

Although numerous studies concerning the pathogenesis of osteonecrosis have been published, the pathophysiologic mechanisms that may be involved continue to be debated. In the early 1980s, the concept of accumulative cell stress was advanced, which is a theory that proposes that bone cells are exposed to multiple insults or stresses, the effects of which accumulate to the point that the cells cannot sustain themselves and die. Technologic advances have led scientists to a better understanding of cell and molecular biology, and recent studies of osteonecrosis and its risk factors have indicated that this concept should be revisited. It now appears that using the term "necrosis" may be incorrect and that apoptosis may play a significant role. Research on osteoporosis, fracture healing, bone graft incorporation, hematology, and genetics may lend insight into the etiology and pathogenesis of osteonecrosis. Several studies on osteoporosis have focused on the effect of exogenous glucocorticoids on the behavior of osteocytes, osteoblasts, osteocytes, and their precursors. Recent findings on osteonecrosis and bone biology are placed into the context of what has been previously reported.

Entities:  

Mesh:

Year:  2007        PMID: 17472306

Source DB:  PubMed          Journal:  Instr Course Lect        ISSN: 0065-6895


  19 in total

1.  Therapeutic effect of minimally invasive decompression combined with impaction bone grafting on osteonecrosis of the femoral head.

Authors:  Hong-Jun Zhang; You-Wen Liu; Zhi-Qian Du; Huili Guo; Ke-Jie Fan; Guo-Hui Liang; Xing-Cai Liu
Journal:  Eur J Orthop Surg Traumatol       Date:  2012-11-27

Review 2.  Cytotherapy of osteonecrosis of the femoral head: a mini review.

Authors:  You-Shui Gao; Chang-Qing Zhang
Journal:  Int Orthop       Date:  2010-04-02       Impact factor: 3.075

3.  A rat model of early stage osteonecrosis induced by glucocorticoids.

Authors:  Mohammad Amin Kerachian; Edward J Harvey; Denis Cournoyer; Terry Y Chow; Ayoub Nahal; Chantal Séguin
Journal:  J Orthop Surg Res       Date:  2011-12-21       Impact factor: 2.359

4.  MDR1 gene polymorphisms are associated with glucocorticoid-induced avascular necrosis of the femoral head in a Chinese population.

Authors:  Yun Xue; Zhan-Qin Zhao; Dun Hong; Hong-Jun Zhang; Hai-Xiao Chen; Shun-Wu Fan
Journal:  Genet Test Mol Biomarkers       Date:  2014-01-04

5.  Pain relief following osteonecrosis of the femoral head treated by free vascularized fibular grafting.

Authors:  Sheng-Bao Chen; You-Shui Gao; Zhen-Hong Zhu; Dong-Xu Jin; Xiang-Guo Cheng; Chang-Qing Zhang
Journal:  Eur J Orthop Surg Traumatol       Date:  2011-11-15

6.  SAS weekly rounds: avascular necrosis.

Authors:  Thomas W Hamilton; Susan M Goodman; Mark Figgie
Journal:  HSS J       Date:  2009-03-18

7.  Endothelial nitric oxide synthase gene polymorphisms and the risk of osteonecrosis of the femoral head in systemic lupus erythematosus.

Authors:  Hak Soo Kim; Sang-Cheol Bae; Tae-Ho Kim; Shin-Yoon Kim
Journal:  Int Orthop       Date:  2013-06-18       Impact factor: 3.075

8.  An animal model of femoral head osteonecrosis induced by a single injection of absolute alcohol: an experimental study.

Authors:  Zhen-Hong Zhu; You-Shui Gao; Shi-Hua Luo; Bing-Fang Zeng; Chang-Qing Zhang
Journal:  Med Sci Monit       Date:  2011-04

9.  Pro-osteogenic effects of fibrin glue in treatment of avascular necrosis of the femoral head in vivo by hepatocyte growth factor-transgenic mesenchymal stem cells.

Authors:  Qian Wen; Chaoying Zhou; Wei Luo; Mingqian Zhou; Li Ma
Journal:  J Transl Med       Date:  2014-05-07       Impact factor: 5.531

10.  Functional investigation of bone implant viability using radiotracers in a new model of osteonecrosis.

Authors:  Luis Schiper; Bluma Linkowski Faintuch; Roberto José da Silva Badaró; Erica Aparecida de Oliveira; Victor E Arana Chavez; Elisangela Chinen; Joel Faintuch
Journal:  Clinics (Sao Paulo)       Date:  2016-10-01       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.